CD26/DPPIV cleaves and degrades CXCL12, and in vivo assay found that animals treated with a DPPIV inhibitor had increased prostate cancer cells in all tissues, especially in osseous tissues. This evidence concerns the gene DPP4 and Familial prostate cancer.